Yu Hai, Wu Xinghua, Zhang Yonggang, Jin Zhihong, Li Guoxin, Zhao Haiping
Department of General Surgery, Nanfang Hospital, Southern Medical University Guangzhou, China ; Department of General Surgery, Affilated Renmin Hospital of Inner Mongolia Medical University Huhhot, China.
Department of Feature Section, The Second Affiliated Hospital of Inner Mongolia Medical University Huhhot, China.
Int J Clin Exp Pathol. 2015 Apr 1;8(4):4106-12. eCollection 2015.
Genetic variability of DNA repair mechanisms influences chemotherapy treatment outcome of gastric cancer. We conducted a cohort study to investigate the role of ERCC1-ERCC2 gene polymorphisms in the chemotherapy response and clinic outcome of gastric cancer. Between March 2011 and March 2013, 228 gastric patients who were newly diagnosed with histopathology were enrolled in our study. Genotypes of ERCC1 rs11615, rs3212986, rs2298881 and ERCC2 rs3212986 were conducted by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay. We found that individuals carrying TT genotype of ERCC1 rs11615 and CC genotype of ERCC1 rs2298881 were associated with better response to chemotherapy and longer survival time of gastric cancer. Moreover, individuals with AA genotype of ERCC2 rs1799793 were correlated with shorter survival of gastric cancer. In conclusion, ERCC1 rs11615, rs2298881 and ERCC2 rs1799793 polymorphism play an important role in the treatment outcome of gastric cancer.
DNA修复机制的遗传变异性影响胃癌化疗的治疗结果。我们进行了一项队列研究，以探讨ERCC1-ERCC2基因多态性在胃癌化疗反应和临床结局中的作用。2011年3月至2013年3月期间，228例新诊断为组织病理学的胃癌患者纳入我们的研究。通过聚合酶链反应-限制性片段长度多态性（PCR-RFLP）分析检测ERCC1 rs11615、rs3212986、rs2298881和ERCC2 rs3212986的基因型。我们发现，携带ERCC1 rs11615的TT基因型和ERCC1 rs2298881的CC基因型的个体对化疗反应较好，胃癌患者生存时间较长。此外，ERCC2 rs1799793的AA基因型个体与胃癌患者较短的生存期相关。总之，ERCC1 rs11615、rs2298881和ERCC2 rs1799793多态性在胃癌治疗结局中起重要作用。
